<DOC>
	<DOCNO>NCT00661362</DOCNO>
	<brief_summary>Saxagliptin new investigational medication develop treatment type 2 diabetes . This study design evaluate efficacy safety adult patient inadequate glycaemic control treat metformin addition diet exercise .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Saxagliptin Combination With Metformin Adult Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed Type 2 diabetes Treatment metformin stable dose &gt; 1500 mg/day HbA1c ≥ 7.0 % ≤10.0 % Insulin therapy within one year enrolment ( exception insulin therapy hospitalization use gestational diabetes ) Type 1 diabetes , history ketoacidosis , hyperosmolar nonketonic koma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Incretins</keyword>
</DOC>